SEC filings and other documents

All proposals passed, with directors elected and auditor ratified; no questions from stockholders.

Next-gen Tablo launch and console refresh cycle set to drive growth and profitability in 2026.

Q1 revenue fell 6% year-over-year, but margin gains and strong pipeline support 2026 growth.

Innovative dialysis solutions and strong recurring revenue drive growth and industry disruption.

Tablo technology drives recurring revenue and improved dialysis outcomes in acute and home markets.

2025 revenue up 5%, gross margin expands, and next-gen Tablo FDA clearance drives 2026 growth.

Operational progress and sales transformation drive confidence despite recent deal timing setbacks.

Revenue guidance cut as large deals shift, but gross margin and demand show strong momentum.

Recurring revenue and rapid acute market growth drive strong financial and operational performance.

Q2 revenue up 15% to $31.4M; gross margin expands; 2025 guidance raised to $122–$126M.

Commercial transformation and technology focus drive margin growth and profitability outlook.

All proposals, including director elections and plan amendments, were approved without contest.

Strong Q1 results and commercial transformation set the stage for sustained growth and profitability.

Q1 revenue up 6% to $29.8M, gross margin expands, and profitability outlook remains strong.

Tablo transforms dialysis delivery with cost savings, clinical impact, and scalable growth.

Tablo transforms dialysis delivery with cost-saving, scalable technology and strong recurring revenue.

Poised for growth in 2025, driven by Tablo's market expansion, cost savings, and sales transformation.

Recurring revenue and gross margin grew, with 2025 guidance targeting further expansion.